What was checked
A cancer vaccine designed using each patient’s own tumor mutations reduced risk of melanoma returning or death by 42% in 1,137-person trial (82% vs 70% alive without recurrence)
Assessment summary
AccurateThe INTerpath-001 trial enrolled exactly 1,137 patients with high-risk melanoma, as confirmed by multiple independent sources including clinical trial registries and medical institutions.